Prostate Cancer Management with Multi-Modality Imaging

描述(申请人提供)：除了传统的结构成像技术、计算机断层扫描(CT)、磁共振成像(MRI)和经直肠超声成像(TRUS)外，非侵入性成像技术(包括放射性核素成像和磁共振波谱成像(MRSI))在前列腺癌治疗方面取得了实质性进展。然而，没有一种单一的成像技术证明了评估前列腺癌所需的功能的广度。此外，使用这些已经可用的成像技术的连贯的多模式方法还没有被建立用于这种疾病的临床治疗。因此，我们建议开发一种方法，为同一患者提供一套全面的功能、代谢、生物分子和结构成像模式，以改善前列腺癌患者的管理。该项目的目标是开发一种结合来自多种成像模式的信息的方法，并开发一种方法来改善当前前列腺癌治疗前和治疗后的管理。在这项研究中，我们将集中在项目初期使用铟-111放射性标记的单抗和MRI/MRSI技术的双模式SPECT/CT成像。 目标1：将开发一种方法来量化111ln标记的己丙肽(ProstaScint(R)，Cytogen公司，普林斯顿，新泽西州)在幻影和使用商业SPECT/CT系统的患者(Discovery VH Hawkeye，GE Healthcare，Waukeha，WL)中的活性。然后，量化111ln-ProstaScint(R)摄取的方法将扩展到结合SPECT/CT和MRI/MRSI评估前列腺癌的方法。 目标2：我们将开发将SPECT/CT和MRI/MRSI图像相关联的方法，以评估具有高转移癌症风险的患者，以帮助制定放射治疗计划。从目标1和2发展而来的111ln-ProstaScint(R)SPECT/CT和MRI/MRSI研究的定量测量和相关性可以指导将在目标3下进行的放射治疗计划。 目标3：开发一种在放射治疗计划中实现相关图像呈现的方法。 我们相信，成功完成拟议研究计划的结果不仅将加强前列腺癌的临床管理，而且将为候选人提供宝贵的能力、技能和知识，使其成为具有深厚量化科学背景的独立生物医学研究人员。

DESCRIPTION (provided by applicant): Substantial advances in prostate cancer management have been made with noninvasive imaging techniques including radionuclide imaging and magnetic resonance spectroscopy imaging (MRSI) in addition to conventional structural imaging techniques, computed tomography (CT), magnetic resonance imaging (MRI), and transrectal ultrasonography (TRUS). However, no single imaging technique has demonstrated the breadth of functionality needed to assess prostate cancer. In addition, a coherent multimodality approach using these already available imaging techniques has not been established for the clinical management of this disease. We therefore propose to develop an approach to present a comprehensive set of functional, metabolic, biomolecular, and structural imaging modalities for the same patient to improve management of patients with prostate cancer. The goal of this project is to develop an approach that combines information from multiple imaging modalities and to develop a method to improve the current prostate cancer management in both pretherapy and posttherapy cases. In this study, we will focus on the dual-modality SPECT/CT imaging using an indium-111 radiolabeled monoclonal antibody and MRI/MRSI techniques during initial periods of the project. Goal 1: A method will be developed to quantify 111ln-labeled capromab pendetide (ProstaScint(R), Cytogen Corporation, Princeton, NJ) activity in phantoms and patients with a commercial SPECT/CT system (Discovery VH Hawkeye, GE Healthcare, Waukesha, Wl). The methods of quantifying 111ln-ProstaScint(R) uptake then will be extended to an approach that combines SPECT/CT and MRI/MRSI for assessment of prostate cancer. Goal 2: We will develop methods that correlate SPECT/CT and MRI/MRSI images to evaluate patients at a high risk of having metastasized cancer with a goal of assisting radiation treatment planning. The quantitative measurements and correlations from 111ln-ProstaScint( R)SPECT/CT and MRI/MRSI studies developed from Goal 1 and 2 then can guide radiation therapy planning which will be pursued under Goal 3. Goal 3: A method to implement the correlative image presentation in radiation treatment planning will be developed. We believe that outcomes from the successful completion of the proposed research program will not only enhance the clinical prostate cancer management but also provide valuable aptitude skills and knowledge for the candidate to become an independent biomedical researcher with strong background in quantitative sciences.